Extensively Drug-Resistant Tuberculosis in India: Prevalence, Incidence and Burden
Received Date: May 03, 2018 / Accepted Date: May 26, 2018 / Published Date: May 31, 2018
Abstract
Extensively Drug-Resistant Tuberculosis (XDR-TB) is a recent challenge for tuberculosis control program. The absence of the functional drugs and high rate of the failure in treatment and mortality rate also high jeopardize for epidemiology. Its prevalence is unknown in India as there was no nationwide counselling. Globally, there were an estimated 55,100 new extensively drug resistant tuberculosis cases in the year of 2015 in 117 countries. However, only 30 cases extensively drug-resistant tuberculosis was reported. Drug susceptibility test (DST) is the cornerstone to diagnose extensively drug resistant tuberculosis, but the lack of laboratory facilities in the resource-limited endemic countries limits its uses. A few new drugs including bedaquiline and delamanid have the potential to improve the efficiency of extensively drug-resistant tuberculosis treatment, but those drugs are used in 39 countries only. The costs of extensively drug resistant tuberculosis treatment (XDR-TB) are several folds higher than then multi drug-resistant tuberculosis (MDR-TB).
Keywords: XDR-TB; DST; MDR-TB; India
Citation: Vadthyavath D, Muragundi PM (2018) Extensively Drug-Resistant Tuberculosis in India: Prevalence, Incidence and Burden. J Infect Dis Ther 6: 365. Doi: 10.4172/2332-0877.1000365
Copyright: © 2018 Vadthyavath D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Recommended Journals
Open Access Journals
Article Tools
Article Usage
- Total views: 3810
- [From(publication date): 0-2018 - Nov 21, 2024]
- Breakdown by view type
- HTML page views: 3105
- PDF downloads: 705
